elranatamab
pfizer
['multiple myeloma', 'multiplemyeloma', 'elranatamab']
the myeloma center was involved with a phase 2 #clinicaltrial presented at #ash22 evaluating the bispecific antibody elranatamab for relapsed/refractory #multiplemyeloma. dr. breaks down the #research: 
The Weill Cornell Medicine (WCM) Myeloma Center is a comprehensive program providing outstanding patient care and conducting world-class research.